Judson Menefee, MD
Endocrinology, Diabetes & Metabolism · Fairhope, ALNPI 1407957046
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $134,856 of the $167,540 with a category attached, or 80.5%. Novo Nordisk accounts for 77.5% of it on its own, with 46 other manufacturers making up the rest. Reporting peaked in 2019 at $56,173 and has fallen 97.3% since, to $1,532 in 2025. Among endocrinology, diabetes & metabolism clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,310 payments — averaging $127.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$130K
- Lilly USA, LLC$14K
- Boehringer Ingelheim$13K
- Bayer$2K
- AstraZeneca$1K
- Amgen$991
- plus $7K from 41 others
Across 3 payments — averaging $5802.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$17K
What the payments were for
- Consulting fees$2,9252%
- Speaking & faculty fees$134,85680%
- Travel & lodging$6,3484%
- Food & beverage$23,07214%
- Education$3390%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$167,540 in reported general payments places this provider in the 90th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
See all endocrinology, diabetes & metabolism providers in Alabama →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 599 | $953,736 |
| MounjaroTirzepatide | 242 | $327,385 |
| JardianceEmpagliflozin | 219 | $273,725 |
| Tresiba Flextouch U-200Insulin Degludec | 144 | $247,523 |
| FarxigaDapagliflozin Propanediol | 230 | $242,582 |
| TrulicityDulaglutide | 91 | $119,629 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 71 | $94,066 |
| Tresiba Flextouch U-100Insulin Degludec | 100 | $77,411 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 78 | $72,507 |
| KerendiaFinerenone | 46 | $57,500 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 23 | $53,199 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 50 | $42,376 |
| Humalog Kwikpen U-100Insulin Lispro | 92 | $42,196 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 29 | $40,909 |
| Humalog Kwikpen U-200Insulin Lispro | 18 | $34,050 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $129,783 | $953,736599 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $13,765 | $466,799420 claims |
| Boehringer IngelheimJardiance | $13,332 | $273,725219 claims |
| AstraZenecaFarxiga | $1,019 | $242,582230 claims |
| BayerKerendia | $1,583 | $57,50046 claims |
| MerckJanumet Xr, Januvia | $422 | $24,52030 claims |
| AmgenProlia | $991 | $22,42013 claims |
| PfizerGenotropin | $21 | $18,73011 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $462 | $12,73324 claims |
| AbbVieSynthroid | $215 | $8,78078 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $45 | $7,726543 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
Other endocrinology, diabetes & metabolism in Fairhope
- Michael HenniganFairhope$25K
- Neil SchaffnerOpelika$642K
- Ralph TeagueBirmingham$487K
- Bantwal BaligaOpelika$483K
- William GarveyBirmingham$421K
- William DebellTuscaloosa$161K
- Edison GoncalvesBirmingham$142K
- David BellIrondale$112K
- Bethany JacksonFlorence$90K
- Dwain WoodeHuntsville$78K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.